vs

Side-by-side financial comparison of Bridger Aerospace Group Holdings, Inc. (BAER) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $8.5M, roughly 1.5× Bridger Aerospace Group Holdings, Inc.). Bridger Aerospace Group Holdings, Inc. runs the higher net margin — -177.2% vs -1398.3%, a 1221.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -45.2%). Bridger Aerospace Group Holdings, Inc. produced more free cash flow last quarter ($-78.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 24.6%).

Bridger Aerospace is an American aerospace company which provides aerial firefighting and wildfire management services. The company has supported firefighting efforts in 24 U.S. states and two Canadian provinces.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BAER vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.5× larger
RNA
$12.5M
$8.5M
BAER
Growing faster (revenue YoY)
RNA
RNA
+479.2% gap
RNA
434.0%
-45.2%
BAER
Higher net margin
BAER
BAER
1221.1% more per $
BAER
-177.2%
-1398.3%
RNA
More free cash flow
BAER
BAER
$78.5M more FCF
BAER
$-78.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
24.6%
BAER

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BAER
BAER
RNA
RNA
Revenue
$8.5M
$12.5M
Net Profit
$-15.1M
$-174.4M
Gross Margin
-65.1%
Operating Margin
-175.0%
-1513.5%
Net Margin
-177.2%
-1398.3%
Revenue YoY
-45.2%
434.0%
Net Profit YoY
-17.9%
-117.0%
EPS (diluted)
$-0.26
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAER
BAER
RNA
RNA
Q4 25
$8.5M
Q3 25
$67.9M
$12.5M
Q2 25
$30.8M
$3.8M
Q1 25
$15.6M
$1.6M
Q4 24
$15.6M
$3.0M
Q3 24
$64.5M
$2.3M
Q2 24
$13.0M
$2.0M
Q1 24
$5.5M
$3.5M
Net Profit
BAER
BAER
RNA
RNA
Q4 25
$-15.1M
Q3 25
$34.5M
$-174.4M
Q2 25
$308.0K
$-157.3M
Q1 25
$-15.5M
$-115.8M
Q4 24
$-12.8M
$-102.3M
Q3 24
$27.3M
$-80.4M
Q2 24
$-10.0M
$-70.8M
Q1 24
$-20.1M
$-68.9M
Gross Margin
BAER
BAER
RNA
RNA
Q4 25
-65.1%
Q3 25
68.9%
Q2 25
39.2%
Q1 25
-10.0%
Q4 24
1.2%
Q3 24
64.3%
Q2 24
24.2%
Q1 24
Operating Margin
BAER
BAER
RNA
RNA
Q4 25
-175.0%
Q3 25
57.5%
-1513.5%
Q2 25
18.0%
-4448.7%
Q1 25
-64.9%
-8360.9%
Q4 24
-48.0%
-4069.6%
Q3 24
50.9%
-4200.9%
Q2 24
-36.5%
-4040.4%
Q1 24
-278.0%
-2178.6%
Net Margin
BAER
BAER
RNA
RNA
Q4 25
-177.2%
Q3 25
50.8%
-1398.3%
Q2 25
1.0%
-4089.3%
Q1 25
-99.3%
-7360.0%
Q4 24
-82.4%
-3439.5%
Q3 24
42.4%
-3441.7%
Q2 24
-76.7%
-3461.8%
Q1 24
-364.8%
-1943.4%
EPS (diluted)
BAER
BAER
RNA
RNA
Q4 25
$-0.26
Q3 25
$0.37
$-1.27
Q2 25
$-0.12
$-1.21
Q1 25
$-0.41
$-0.90
Q4 24
$-0.24
$-0.80
Q3 24
$0.31
$-0.65
Q2 24
$-0.33
$-0.65
Q1 24
$-0.55
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAER
BAER
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$31.4M
$350.2M
Total DebtLower is stronger
$222.5M
Stockholders' EquityBook value
$-342.6M
$1.9B
Total Assets
$330.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAER
BAER
RNA
RNA
Q4 25
$31.4M
Q3 25
$55.1M
$350.2M
Q2 25
$17.0M
$243.9M
Q1 25
$22.3M
$254.2M
Q4 24
$39.3M
$219.9M
Q3 24
$33.3M
$370.2M
Q2 24
$8.5M
$575.8M
Q1 24
$6.8M
$471.4M
Total Debt
BAER
BAER
RNA
RNA
Q4 25
$222.5M
Q3 25
Q2 25
Q1 25
Q4 24
$208.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BAER
BAER
RNA
RNA
Q4 25
$-342.6M
Q3 25
$-322.4M
$1.9B
Q2 25
$-351.0M
$1.2B
Q1 25
$-347.4M
$1.3B
Q4 24
$-326.7M
$1.4B
Q3 24
$-304.4M
$1.5B
Q2 24
$-328.0M
$1.2B
Q1 24
$-348.7M
$830.9M
Total Assets
BAER
BAER
RNA
RNA
Q4 25
$330.3M
Q3 25
$311.0M
$2.1B
Q2 25
$279.0M
$1.4B
Q1 25
$275.6M
$1.5B
Q4 24
$290.8M
$1.6B
Q3 24
$307.3M
$1.6B
Q2 24
$281.7M
$1.3B
Q1 24
$252.4M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAER
BAER
RNA
RNA
Operating Cash FlowLast quarter
$-8.0M
$-156.2M
Free Cash FlowOCF − Capex
$-78.4M
$-156.9M
FCF MarginFCF / Revenue
-917.3%
-1257.6%
Capex IntensityCapex / Revenue
823.4%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-64.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAER
BAER
RNA
RNA
Q4 25
$-8.0M
Q3 25
$41.0M
$-156.2M
Q2 25
$1.4M
$-199.7M
Q1 25
$-17.7M
$-124.8M
Q4 24
$54.5M
$-99.9M
Q3 24
$200.0K
$-65.6M
Q2 24
$-22.6M
$-65.0M
Q1 24
$-22.8M
$-70.4M
Free Cash Flow
BAER
BAER
RNA
RNA
Q4 25
$-78.4M
Q3 25
$34.6M
$-156.9M
Q2 25
$515.0K
$-203.0M
Q1 25
$-21.0M
$-128.6M
Q4 24
$53.5M
$-103.8M
Q3 24
$-951.0K
$-67.3M
Q2 24
$-23.6M
$-65.5M
Q1 24
$-23.7M
$-71.3M
FCF Margin
BAER
BAER
RNA
RNA
Q4 25
-917.3%
Q3 25
51.0%
-1257.6%
Q2 25
1.7%
-5277.1%
Q1 25
-134.0%
-8174.3%
Q4 24
343.5%
-3491.0%
Q3 24
-1.5%
-2881.8%
Q2 24
-181.3%
-3204.6%
Q1 24
-430.7%
-2012.3%
Capex Intensity
BAER
BAER
RNA
RNA
Q4 25
823.4%
Q3 25
9.3%
5.7%
Q2 25
3.0%
86.9%
Q1 25
21.2%
238.6%
Q4 24
6.3%
131.7%
Q3 24
1.8%
72.9%
Q2 24
7.6%
26.0%
Q1 24
17.4%
25.8%
Cash Conversion
BAER
BAER
RNA
RNA
Q4 25
Q3 25
1.19×
Q2 25
4.68×
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons